Mary Grecco

DocwireNews

Results of a study that sought to determine a dynamic pattern of ctDNA during hypofractionated radiation therapy (RT) and its clinical relevance among patients with pathologically or clinically diagnosed early-stage lung cancer were presented at the ESMO Congress 2023.
Patients who underwent definitive RT alone were enrolled prospectively. RT was curatively prescribed with 60 to 64 Gy in 4 to 20 fractions. Blood samples were obtained before and after the start of RT, including the first, second, and third day (T0-3), and ctDNA was longitudinally analyzed. A total of 13 patients were ultimately evaluated, excluding undetected cases or patients without samples within 3 days after starting RT. The researchers used comprehensive variables quantifying various types of ctDNA, including sum of variant allele frequency (total VAF, %), maximum of VAF (%), sum of genomic equivalent (total GE, hGE/mL), and maximum of GE (max GE, hGE/mL) to find a feasible index associated with progression.
Results showed that during a median 22.2-month follow-up, four patients experienced progressive disease (PD) between 7.9 and 16.6 months after RT (PD group); two experienced local or locoregional recurrence and two had lung-to-lung metastasis. The remaining nine patients exhibited no evidence of disease (NED group) but showed the highest ctDNA ratio [NJ1; 1.76-2.34) compared with the baseline level. With regard to the timing of ctDNA elevation, the researchers found that the Tmax, the day with the highest ctDNA level among T0-3, was significantly different between the NED and PD groups with total GE and max GE (P=.035 and P=.021, respectively). At ROC curves, the max GE showed the best AUC (86.1%), and the cutoff value of the Tmax was 1.5 (sensitivity, 55.6%; specificity, 100%; positive-predictive value, 100%; negative-predictive value, 50.0%). Tumor size greater than 0.3 cm, squamous histology, and daily dose of 3-4 Gy were correlated to the Tmax T2 or T3. At survival analysis, only Tmax showed better disease control rate, which was marginally significant (P=.081).
The researchers concluded that the timing of early ctDNA elevation after RT may be a potential predictive marker of good clinical response. They also suggested that “max GE was a feasible index to check ctDNA level after RT.”
Source: Yang K, Noh JM, Kim YJ, Pyo H. Early dynamics of circulating tumor DNA following curative hypofractionated radiotherapy related to disease control in lung cancer. Abstract of a poster presented at the ESMO Congress 2023; October 20-24, 2023; Madrid, Spain.

Emily Menendez

Zanidatamab Gains Accelerated Approval by FDA for Metastatic HER2+ BTC

Bile Duct Cancer

Laura Litwin

Phase 2 Study Evaluates Maintenance Atezolizumab Plus Talazoparib in ES-SCLC

Small Cell Lung Cancer

Rob Dillard

Remote Telemedicine Highly Accurate at Diagnosing Melanoma

Melanoma

Latest News

ctDNA After Hypofractionated Radiation Therapy in Patients With Lung Cancer

ESMO 2023: Focus on Lung Cancer

Results of a study that sought to determine a dynamic pattern of ctDNA during hypofractionated radiation therapy.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe